Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
Beijing, CN
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments. The company's drug development portfolio currently features a dozen key product candidates; specifically, two are actively progressing through multi-regional Phase II clinical trials, while another pair is in Phase I clinical assessments. Their therapeutic focus spans critical health areas such as oncology, autoimmune disorders, inflammatory conditions, metabolic diseases, and other ailments. Supporting these pharmaceutical ventures, the broader Beijing Biocytogen Co., Ltd. group, which commenced operations in 2008, also in Beijing, specializes in the creation and large-scale distribution of genetically modified animal models. This group provides comprehensive preclinical research services, leveraging its expertise in advanced gene-humanized models, patient-derived xenograft (PDX) models, and human immune system reconstituted models. Their extensive catalog includes a diverse array of specialized gene-edited mice and rats – for example, B-NDG mice, various Cre and knockout (KO) lines (like B-p53 KO and B-ApoE KO), knock-in (KI) models, B-hFcgrt (FcRn) mice, in addition to genome-edited human embryonic stem cells (hESC) and luciferase-reporter stable tumor cell lines. Furthermore, this overarching Biocytogen entity has cultivated an advanced platform dedicated to antibody discovery and development. It offers specialized pharmacology services across vital domains including tumor immunology, general oncology, autoimmune research, and both in vivo and in vitro pharmacological evaluations. The group also makes its products accessible through online sales channels. Beyond its primary location in Beijing, China, the company maintains additional facilities in Haimen, Jiangsu, and Shanghai, China, as well alongside international branches in Heidelberg, Germany, and Boston, United States.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.65% | -0.88% | -5.69% | -5.51% | +55.41% | +40.00% | +177.64% | +112.10% | +90.08% | +90.08% | +90.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-07 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Biotechnology: +1.6%+40.6% ★ Q4'25: +94.3% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+410.1% ★ Q4'25: +164.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+14.3% ★ Q4'25: +13.8% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+18.8% ★ Q4'25: +20.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+19.9% ★ Q4'25: +51.2% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+0.5% ★ Q4'25: +0.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.39× ★ Q4'25: 0.63× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
533.88M
est: 603.37M (-11.5%)
|
716.91M
est: 1.47B (-51.3%)
|
980.45M
est: 946.74M (+3.6%)
|
1.38B
est: 1.37B (+1.0%)
|
1.97B
1.97B – 1.97B
+44.5% YoY
|
2.60B
2.60B – 2.60B
+31.9% YoY
|
3.41B
3.41B – 3.41B
+31.1% YoY
|
| EBITDA |
-465.86M
est: -325.73M (-43.0%)
|
-97.87M
est: -410.38M (+76.2%)
|
303.80M
est: -264.14M (+215.0%)
|
419.49M
est: -381.04M (+210.1%)
|
-550.60M
-550.60M – -550.60M
-44.5% YoY
|
-726.34M
-726.34M – -726.34M
-31.9% YoY
|
-951.98M
-951.98M – -951.98M
-31.1% YoY
|
| EBIT |
-604.60M
est: -392.64M (-54.0%)
|
-280.31M
est: -607.73M (+53.9%)
|
134.62M
est: -391.16M (+134.4%)
|
259.03M
est: -564.28M (+145.9%)
|
-815.37M
-815.37M – -815.37M
-44.5% YoY
|
-1.08B
-1.08B – -1.08B
-31.9% YoY
|
-1.41B
-1.41B – -1.41B
-31.1% YoY
|
| Net Income |
-602.16M
est: -561.80M (-7.2%)
|
-382.95M
est: 499.88M (-176.6%)
|
33.54M
est: -43.99M (+176.2%)
|
173.20M
est: 147.97M (+17.1%)
|
314.76M
314.76M – 314.76M
+112.7% YoY
|
496.63M
496.63M – 496.63M
+57.8% YoY
|
738.10M
738.10M – 738.10M
+48.6% YoY
|
| SGA |
313.66M
est: 225.89M (+38.9%)
|
349.09M
est: 564.13M (-38.1%)
|
311.35M
est: 363.10M (-14.3%)
|
400.45M
est: 523.80M (-23.5%)
|
756.88M
756.88M – 756.88M
+44.5% YoY
|
998.46M
998.46M – 998.46M
+31.9% YoY
|
1.31B
1.31B – 1.31B
+31.1% YoY
|
| EPS |
-1.53
est: -1.41 (-8.4%)
|
-0.96
est: 1.25 (-176.8%)
|
0.08
est: -0.11 (+176.7%)
|
0.43
est: 0.37 (+16.3%)
|
0.79
0.79 – 0.79
+112.7% YoY
|
1.24
1.24 – 1.24
+57.8% YoY
|
1.84
1.84 – 1.84
+48.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 4/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.25% | 163.7K | 0.59% |
| 2 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 167.8K | 0.72% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.04% | 26.6K | 0.74% |
| 4 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.04% | 255.4K | 0.65% |
| 5 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 79.9K | 0.74% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 136.4K | 0.55% |
| 7 | Amundi Prime Emerging Markets UCITS ETF DR (C) PRAM.L | 0.00% | 74.1K | 0.10% |
| 8 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 9.7K | 0.35% |
| 9 | iShares Core MSCI Emerging Markets IMI Index ETF XEC.TO | 0.00% | 99.4K | 0.28% |
| 10 | JPMorgan BetaBuilders Emerging Markets Equity ETF BBEM | 0.00% | 23.4K | 0.15% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuelei Shen | Chairman of the Board, Chief Executive Officer & GM | 5M | — |
| Jian Ni | Executive Director | 693.4K | — |
| Qingcong Lin | Deputy GM & Chief Executive Officer of Biocytogen Boston Corporation | — | — |
| Bin Liu | Chief Financial Officer | — | male |
| Yi Yang | Chief Scientific Officer & Deputy GM | — | — |
| Yongliang Wang | Deputy GM & Secretary | — | male |
| Wai Ching Au | Joint Company Secretary | — | female |
| Chunli Sun | Director of Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2315.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
